Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.

Hutson TE, Bellmunt J, Porta C, Szczylik C, Staehler M, Nadel A, Anderson S, Bukowski R, Eisen T, Escudier B; Sorafenib TARGET Clinical Trial Group.

Eur J Cancer. 2010 Sep;46(13):2432-40. doi: 10.1016/j.ejca.2010.06.121. Epub 2010 Jul 23.

PMID:
20656473
2.

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM.

J Clin Oncol. 2009 Jul 10;27(20):3312-8. doi: 10.1200/JCO.2008.19.5511. Epub 2009 May 18.

3.

Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET.

Negrier S, Jäger E, Porta C, McDermott D, Moore M, Bellmunt J, Anderson S, Cihon F, Lewis J, Escudier B, Bukowski R.

Med Oncol. 2010 Sep;27(3):899-906. doi: 10.1007/s12032-009-9303-z. Epub 2009 Sep 12.

PMID:
19757215
4.

Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.

Hutson TE.

Expert Rev Anticancer Ther. 2007 Sep;7(9):1193-202. Review.

PMID:
17892420
5.

Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.

Bukowski RM, Stadler WM, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Figlin RA.

Oncology. 2010;78(5-6):340-7. doi: 10.1159/000320223. Epub 2010 Aug 20.

PMID:
20733337
6.

Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.

Naito S, Tsukamoto T, Murai M, Fukino K, Akaza H.

BJU Int. 2011 Dec;108(11):1813-9. doi: 10.1111/j.1464-410X.2011.10281.x. Epub 2011 Apr 11.

7.

Sorafenib TARGET trial results in Spanish patients.

Bellmunt J, González-Larriba JL, Climent MA, López-Vivanco G, Urruticoechea L, Albanell J.

Clin Transl Oncol. 2007 Oct;9(10):671-3.

PMID:
17974528
8.

Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.

Beck J, Procopio G, Bajetta E, Keilholz U, Negrier S, Szczylik C, Bokemeyer C, Bracarda S, Richel DJ, Staehler M, Strauss UP, Mersmann S, Burock K, Escudier B.

Ann Oncol. 2011 Aug;22(8):1812-23. doi: 10.1093/annonc/mdq651. Epub 2011 Feb 15.

9.

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.

Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM; ARCCS Study Investigators.

Cancer. 2010 Mar 1;116(5):1272-80. doi: 10.1002/cncr.24864.

10.

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.

Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ.

J Clin Oncol. 2006 Jun 1;24(16):2505-12. Epub 2006 Apr 24.

11.

Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.

La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB.

Am J Clin Oncol. 2010 Jun;33(3):217-20. doi: 10.1097/COC.0b013e3181a650a6.

PMID:
19745694
12.

Sorafenib for the treatment of advanced renal cell carcinoma.

Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R, Pazdur R.

Clin Cancer Res. 2006 Dec 15;12(24):7271-8. Review.

13.

Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.

Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S.

Jpn J Clin Oncol. 2007 Oct;37(10):755-62. Epub 2007 Oct 19.

14.

Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.

Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE.

J Clin Oncol. 2010 Feb 20;28(6):1054-60. doi: 10.1200/JCO.2009.24.9730. Epub 2010 Jan 19.

15.

Sorafenib: in advanced renal cancer.

McKeage K, Wagstaff AJ.

Drugs. 2007;67(3):475-83; discussion 484-5. Review.

PMID:
17335301
16.

Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice.

Tanigawa G, Kawashima A, Yamaguchi S, Nishimura K, Miyoshi S, Kajikawa J, Meguro N, Yosioka T, Oka T, Hara T, Takayama H, Nonomura N; Osaka Renal Cell Carcinoma Clinical Study Collaboration.

Jpn J Clin Oncol. 2011 Nov;41(11):1265-70. doi: 10.1093/jjco/hyr137. Epub 2011 Sep 29.

17.

Incidence of brain metastases in renal cell carcinoma treated with sorafenib.

Massard C, Zonierek J, Gross-Goupil M, Fizazi K, Szczylik C, Escudier B.

Ann Oncol. 2010 May;21(5):1027-31. doi: 10.1093/annonc/mdp411. Epub 2009 Oct 22.

18.

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.

Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, Negrier S, Laferriere N, Scheuring UJ, Cella D, Shah S, Bukowski RM.

J Clin Oncol. 2009 Mar 10;27(8):1280-9. doi: 10.1200/JCO.2008.19.3342. Epub 2009 Jan 26. Erratum in: J Clin Oncol. 2009 May 1; 27(13):2305.

19.

Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.

Escudier B, Lassau N, Angevin E, Soria JC, Chami L, Lamuraglia M, Zafarana E, Landreau V, Schwartz B, Brendel E, Armand JP, Robert C.

Clin Cancer Res. 2007 Mar 15;13(6):1801-9.

20.

Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial.

Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H, Middleton R, Cihon F, Anderson S, Shah S, Bukowski R, Escudier B; TARGET Study Group.

J Natl Cancer Inst. 2008 Oct 15;100(20):1454-63. doi: 10.1093/jnci/djn319. Epub 2008 Oct 7.

Items per page

Supplemental Content

Write to the Help Desk